Navigation Links
FDA Grants Resverlogix Approval to Commence a Phase 1 Clinical Trial for RVX-208
Date:12/10/2007

New class of ApoA-I/HDL drugs to reverse atherosclerosis enters the clinic

TSX Exchange Symbol: RVX

CALGARY, Dec. 10 /PRNewswire-FirstCall/ - Resverlogix Corp. ("Resverlogix") (TSX:RVX) announced today that it has received approval by the US Food and Drug Administration (FDA) to initiate a Phase 1a clinical trial of oral RVX-208 in the USA. RVX-208 is a novel first-in-class small molecule that increases the production of ApoA-I and HDL. ApoA-I is regarded as the critical cardioprotective protein for the treatment of cardiovascular diseases.

The Phase I clinical trial is taking place at a leading US contract research organization. The trial consist of three arms, an ascending single dose, a fed and fasted dose effect study, and a 7-day ascending multiple dose that will enroll a total of 70-80 healthy volunteers. The primary objective of the trial is to evaluate oral RVX-208 in healthy adult subjects for safety, tolerability, and pharmacokinetics. Results from this Phase 1a trial will be used for optimizing dosing for future trials including our Phase 1b trial.

Gregory S. Wagner, PhD, Senior Vice President, Preclinical Development of Resverlogix, stated that, "RVX-208 possesses a very favorable pharmacological and pharmaceutical profile. This compound is an excellent choice to be the first drug candidate from our preclinical pipeline, our research and development team has worked aggressively to rapidly advance it into clinical development."

"This field has been developing for 50 years. In multiple human and animal studies over-expression or repeated infusion of ApoA-I inhibit progression and induce regression of atherosclerosis in both animals and humans," stated Dr. Jan Johansson, MD, PhD. Senior Vice President of Clinical Affairs of Resverlogix. "We have identified a way to increase the endogenous production of ApoA-I via a small molecule drug. The initiation of this clinical trial is a milestone for the fi
'/>"/>

SOURCE Resverlogix Corp.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Mirus Bio Awarded Grants & Contracts of Over $5 Million
2. FDA Grants Orphan Drug Designation to TREANDA, an Investigational Treatment for Chronic Lymphocytic Leukemia
3. Anesiva Grants Specific-Use License of Its Needle-Free Drug Delivery Technology to Particle Therapeutics for Diabetes Drug
4. NIH grants $750,000 to develop device to determine temperature of neonates brain
5. Edwards Lifesciences Grants UC Irvine $5 Million to Establish the Edwards Lifesciences Center for Advanced Cardiovascular Technology
6. Radius Grants Major Pharmaceutical Company Exclusive Option to License BA058 for Osteoporosis
7. Poniard Pharmaceuticals Announces European Commission Grants Orphan Medicinal Product Designation to Picoplatin for Treatment of Small Cell Lung Cancer
8. CV Therapeutics Reports Option Grants Under Nasdaq Marketplace Rule 4350
9. NASDAQ Panel Grants Merge Technologies Additional Time to Regain Compliance
10. Resverlogix Presents Key Apo-Al/HDL Scientific Data at DALM
11. Resverlogix is Presenting at IAS HDL Workshop
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/21/2015)... 21, 2015 A leading manufacturer of ... slated to discuss its custom fabrication services today at ... website, which launched just prior to the INTERPHEX event. ... 21, 22 and 23) at the Javits Center in ... the world’s largest and most innovative pharmaceutical and biotech ...
(Date:4/20/2015)... and MENLO PARK, Calif. , ... (OTCQX: DMPI) (DelMar and the Company), a ... cancer therapies in new orphan drug indications, today ... Annual Meeting of the American Association for Cancer ... for its lead product candidate VAL-083 ...
(Date:4/20/2015)... Calif. , April 20, 2015 PointCross ... Pvt. Ltd. to provide an integrated Big Data and ... all biomarkers collected in the context of clinical trials ... of precise or multi-targeted drug candidates, stratified patient selection ... disease progression free survival. Highlighting the ...
(Date:4/20/2015)... - Portage Biotech Inc. ("Portage" or "the Company") (OTC ... announce that its wholly owned subsidiary, Portage Pharmaceuticals Ltd. ... one of its proprietary human-derived CPP sequences and a ... of NFkB signalling even if administered when the BBB ... blood brain barrier (BBB) in mice was studied and ...
Breaking Biology Technology:HOLLOWAY AMERICA to Reveal Newly Designed Responsive Website at INTERPHEX 2015 Today 2HOLLOWAY AMERICA to Reveal Newly Designed Responsive Website at INTERPHEX 2015 Today 3DelMar Pharmaceuticals Presents Promising Preclinical Data on VAL-083's Potential to Treat Temozolomide-Resistant Glioblastoma Multiforme (GBM) 2DelMar Pharmaceuticals Presents Promising Preclinical Data on VAL-083's Potential to Treat Temozolomide-Resistant Glioblastoma Multiforme (GBM) 3DelMar Pharmaceuticals Presents Promising Preclinical Data on VAL-083's Potential to Treat Temozolomide-Resistant Glioblastoma Multiforme (GBM) 4DelMar Pharmaceuticals Presents Promising Preclinical Data on VAL-083's Potential to Treat Temozolomide-Resistant Glioblastoma Multiforme (GBM) 5PointCross Life Sciences and InterpretOmics partner for Clinical and Genomic Biomarker Management for Drug Development 2Portage's CPP Platform Delivers a Peptide Cargo Across Blood Brain Barrier 2Portage's CPP Platform Delivers a Peptide Cargo Across Blood Brain Barrier 3
... , a provider of molecular diagnostics solutions, reported losses in ... Wave reported total revenue of $5.8 million and a net ... for the quarter ended June 30, 2005, compared to total ... and zero cents per diluted share for the same period ...
... Third Wave Technologies Inc., a developer and provider ... chairman of the company's board of directors, replacing company ... the business's planned transition. , ,Thompson, 63, was the ... of Abbott Laboratories , an Illinois-based medical products ...
... Corp ., a Waukesha-based supply chain technology ... enabling Cooper Lighting , a George-based ... distribution operations and workforce productivity. , ,The ... with RedPrairie's DLx Warehouse, slotting and workforce ...
Cached Biology Technology:Transition continues to impact Third Wave financials 2
(Date:4/2/2015)... Fingerprint Cards (FPC) has received ... the distributor World Peace Industrial Group (WPI), part of ... the major part of the shipments will take place ... smartphone manufacturers in China . The ... communicated revenue guidance of + 1 000 MSEK for 2015.  ...
(Date:3/30/2015)... --Research and Markets ( http://www.researchandmarkets.com/research/lc9bnl/global_gesture ) has ... Market in Automotive Sector 2014-2018" report to their ... Recognition market in Automotive Sector to grow at a ... Gesture recognition is the ability of a device to ... Gesture recognition technology can be 2D-based or 3D-based. It ...
(Date:3/24/2015)... GARDENS, Fla. , March 24, 2015 /PRNewswire/ ... identity management solutions, today announced that its U.are.U ... clothing accessory retailer Goorin Bros . to ... Crossmatch biometrics-based solution secures access to the POS ... the increased risk of data breaches. ...
Breaking Biology News(10 mins):Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 110 Million 2Global Gesture Recognition Market in Automotive Sector Report 2015 - Growing Number of Partnerships 2Crossmatch Fingerprint Readers Help Retailer Prevent Data Breaches at Point-of-Sale 2
... of a new gene is helping researchers at Michigan ... A team of researchers, led by Katherine Osteryoung, ... a new class of proteins in the ... Academy of Sciences . CLMP1 plays a key role ...
... aid cavity-nesting ducks can prove to be turtle death traps. ... Educator Associate Professor Denis Conover, of the Department of Biological ... he came upon a duck nest box in the wetlands ... over. Turtle corpses were strewn about the mud and mire ...
... living in family or group homes are less ... living in institutions, according to University of Louisville ... Ph.D. These individuals also are more likely than ... increased decay and gum disease, factors that may ...
Cached Biology News:Discovery of new gene could improve efficiency of molecular factories 2UC research finds that a duck's boon might be a turtle's bane 2UofL researcher to develop oral health plan for those with IDD 2
... Hot Start Taq ... activity before the onset ... nonspecific amplification and primer-dimer ... is raised, the antibody ...
... Fluorescein 6-Fam, Hex, Tet Cy3, Cy5, ... Tamra Black Hole Quenchers Molecular Beacons* ... Tamra, Joe 3 Dabcyl Dabcyl*Licensed ... York Double labelled probes are purified either ...
... (rEK) is a highly purified preparation of ... serine protease which recognizes the identical cleavage ... has similar enzymatic activity (1). Novagen&'s enzyme ... to yield the highest activity available, and ...
Angiotensin Converting Enzyme [Porcine Kidney, ACE, Peptidyl-dipeptidase A]...
Biology Products: